<DOC>
	<DOCNO>NCT01364493</DOCNO>
	<brief_summary>Although overall incidence gastric cancer steadily decline many Western country last decade , still one common tumor China . It well recognise combination chemotherapy regimens improve patient outcome , accept global standard regimen advance gastric cancer . The ToGA study first randomize , prospective , multicenter , phase III trial show efficacy safety Trastuzumab HER2- positive GC . Trastuzumab reduce risk death 26 % ( HR 0.74 ; 95 % CI 0∙60 , 0∙91 ; p=0∙0046 ) combine reference chemotherapy ( Capecitabine plus Cisplatin ) prolong median survival nearly 3 month ( 11.1 13.8 month ) patient HER2-positive ( FISH+ IHC3+ ) advance GC . Oxaliplatin show effective cisplatin , exhibit favorable toxicity profile substantially low rate nephrotoxicity , ototoxicity , myelosuppression . In current study , efficacy safety Trastuzumab combination Oxaliplatin/capecitabine chemotherapy evaluate Chinese patient HER2 positive advance recurrent gastric cancer .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Trastuzumab Combination With Capecitabine Oxaliplatin First-line Chemotherapy Inoperable , Locally Advanced Recurrent and/or Metastatic Gastric Cancer</brief_title>
	<detailed_description>Trastuzumab administer load dose 8 mg/kg ( day 1 ) follow 6mg/kg i.v . infusion every 3 week . Trastuzumab continue disease progression intolerable toxicity . Capecitabine ( Xeloda ) 2000mg/m2d , d1-14 ; q3w , disease progression intolerable toxicity . Oxaliplatin 130mg/m2 d1 ; q3w , 6 cycle</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>1 . Histologically confirm adenocarcinoma stomach gastrooesophageal junction inoperable locally advanced recurrent and/or metastatic disease , amenable curative therapy . 2 . Measurable disease , accord Response Evaluation Criteria Solid Tumors ( RECIST 1.0 ) , assess use image technique ( CT MRI ) . 3 . HER2 positive tumour ( primary tumour metastasis ) assess central laboratory . ( Both IHC Dual SISH perform patient central laboratory . ) 4 . ECOG Performance status 0 , 1 2 . 5 . Life expectancy least 3 month . 6 . Male female . Age ≥ 18 year . 7 . Signed informed consent . 1 . Previous chemotherapy advanced/metastatic disease ( prior adjuvant/neoadjuvant therapy allow least 6 month elapse completion adjuvant/neoadjuvant therapy enrolment study ; total dose cisplatin less 300mg/m2 , adjuvant/neoadjuvant therapy oxaplatin allow ) . 2 . No prior use EGFRtargeting drug , Trastuzumab , lapatinib TKIs . 3 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome ( e.g . patient partial total gastrectomy enter study , jejunostomy probe ) . 4 . Patients active ( significant uncontrolled ) gastrointestinal bleeding . 5 . Residual relevant toxicity result previous therapy ( exception alopecia ) , e.g . neurological toxicity ≥ grade 2 NCICTCAE 4.0 . 6 . Other malignancy within last 5 year , except carcinoma situ cervix , basal cell carcinoma . 7 . Neutrophil count &lt; 1.5 × 109/L , hemoglobin &lt; 90 g/L , platelet count &lt; 100 × 109/L . 8 . Serum bilirubin &gt; 1.5 × upper limit normal ( ULN ) ; , AST ALT &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis ) ; , alkaline phosphatase &gt; 2.5 × ULN ( &gt; 5 × ULN patient liver metastasis , &gt; 10 × ULN patient bone liver metastasis ) ; , albumin &lt; 25 g/L . 9 . Creatinine clearance &lt; 60 mL/min . 10 . History document congestive heart failure ; angina pectoris require medication ; evidence transmural myocardial infarction ECG ; poorly control hypertension ( systolic BP &gt; 180 mmHg diastolic BP &gt; 100 mmHg ) ; clinically significant valvular heart disease ; high risk uncontrollable arrhythmia . 11 . Baseline LVEF &lt; 50 % ( measure echocardiography MUGA ) . 12 . Patients dyspnoea rest due complication advance malignancy disease , require supportive oxygen therapy . 13 . Patients receive chronic high dose corticosteroid therapy . ( Inhaled steroid short course oral steroid antiemesis appetite stimulant allow ) . 14 . Clinically significant hearing abnormality . 15 . Known dihydropyrimidine dehydrogenase ( DPD ) deficiency . 16 . History clinical evidence brain metastasis . 17 . Serious uncontrolled systemic intercurrent illness , e.g . infection poorly control diabetes . 18 . Positive serum pregnancy test woman childbearing potential . 19 . Subjects reproductive potential willing use effective method contraception . 20 . Received investigational drug treatment within 4 week start study treatment . 21 . Radiotherapy within 4 week start study treatment ( 2 week interval allow palliative radiotherapy give bone metastastic site peripherally patient recover acute toxicity ; prior adjuvant radiotherapy allow complete least 6 month ) . 22 . Major surgery within 4 week start study treatment , without complete recovery . 23 . Patients know active infection HIV , HBV , HCV . 24 . Known hypersensitivity study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>HER2-positive</keyword>
	<keyword>adenocarcinoma stomach gastro-esophageal junction</keyword>
	<keyword>Inoperable</keyword>
	<keyword>locally advanced</keyword>
	<keyword>recurrent</keyword>
	<keyword>metastatic</keyword>
</DOC>